May 10, 2022 – Page 4 – Turkey News Gazette

May 10, 2022

ROSEN, LEADING INVESTOR COUNSEL, Encourages Cano Health, Inc. f/k/a Jaws Acquisition Corp. Investors with Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action – CANO, CANO.WS, JWS, JWS.U, JWS WS

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Cano Health, Inc. f/k/a Jaws Acquisition Corp. (NYSE: CANO, CANO.WS, JWS, JWS.U, JWS WS) between May 18, 2020 and February 25, 2022, inclusive (the “Class Period”), of the important May 17, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Cano Health securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Cano Health class action, go to https://rosenlegal.com/submit-form/?case_id=4271 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 17, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Cano Health overstated its due diligence efforts and expertise with respect to acquiring target businesses; (2) accordingly, Cano Health performed inadequate due diligence into whether the Company, post-Business Combination, could properly account for the timing of revenue recognition as prescribed by ASC 606, particularly with respect to Medicare risk adjustments; (3) as a result, Cano Health misstated its capitated revenue, direct patient expense, accounts receivable, net of unpaid service provider costs, and accounts payable and accrued expenses; (4) accordingly, Cano Health was at an increased risk of failing to timely file one or more of its periodic financial reports; and (5) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Cano Health class action, go to https://rosenlegal.com/submit-form/?case_id=4271 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

May 10, 2022

ROSEN, LEADING INVESTOR COUNSEL, Encourages Homology Medicines, Inc. Investors with Losses to Secure Counsel Before Important May 24 Deadline in Securities Class Action – FIXX

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Homology Medicines, Inc. (NASDAQ: FIXX) between June 10, 2019 and February 18, 2022, inclusive (the “Class Period”), of the important May 24, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Homology securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Homology class action, go to https://rosenlegal.com/submit-form/?case_id=4851 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 24, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Homology had overstated the efficacy and risk mitigation regarding HMI-102, which is in Phase I/II pheNIX clinical trial and a gene therapy for the treatment of phenylketonuria (PKU) in adults; (2) accordingly, it was unlikely that Homology would be able to commercialize HMI-102 in its present form; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Homology class action, go to https://rosenlegal.com/submit-form/?case_id=4851 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

May 10, 2022

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages International Business Machines Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – IBM

NEW YORK, May 09, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of International Business Machines Corporation (NYSE: IBM) between April 4, 2017 and October 20, 2021, inclusive (the “Class Period”), of the important June 6, 2022 lead plaintiff deadline.

SO WHAT: If you purchased IBM securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the IBM class action, go to https://rosenlegal.com/submit-form/?case_id=5104 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 6, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Strategic Imperatives Revenue and growth, CAMSS (the sectors of “Cloud,” “Analytics,” “Mobile,” “Security,” and “Social”) and CAMSS Components’ revenue and growth, and the Company’s Segments’ revenue and growth were artificially inflated as a result of the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives Revenue; (2) IBM’s present success and positive future growth prospects concerning its Strategic Imperative business strategy were being fueled by the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperative Revenue; (3) as a result of the foregoing, defendants misled the market by portraying IBM’s Strategic Imperative’s financial performance and future prospects more favorable than they actually were as a result of the fraudulent scheme and/or the wrongful reclassification of revenues from non-strategic to strategic to make those revenues eligible for treatment as Strategic Imperatives; and (4) Total Revenue and IBM’s Segments’ revenue and growth were artificially inflated as a result of the fraudulent scheme and/or the wrongful reclassification of revenues from non-strategic to strategic and/or the wrongful recognition of revenue. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the IBM class action, go to https://rosenlegal.com/submit-form/?case_id=5104 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

May 10, 2022

Nyxoah Reports First Quarter 2022 Financial and Operating Results

REGULATED INFORMATION

Nyxoah Reports First Quarter 2022 Financial and Operating Results

Mont-Saint-Guibert, Belgium – May 9, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the first quarter of 2022.

First Quarter 2022 Financial and Operating Highlights

Generated revenue of €660,000 from the commercialization of Genio® in Europe, primarily in Germany, which represents year-over-year growth of more than three-and-and-half times and is more than double what was achieved in the fourth quarter of 2021
Exited the first quarter with 15 active implant sites in Germany, representing 25% growth over Q4 2021; Nyxoah expects to add an extra 10 sites by the end of the third quarter of 2022, bringing the total to 25 active implanting accounts and driving quarterly sales acceleration and market leadership in Germany by the end of 2022
Completed the first commercial Complete Concentric Collapse (CCC) patients in Germany
Accelerated monthly patient enrollment in the DREAM U.S. IDE study and continue to expect implants to be completed in the second quarter of 2022
The U.S. FDA approved Nyxoah’s request to reduce the sample size in DREAM to 115 patients from the original 134, driven by new and favorable data from the BETTER SLEEP study; aside from the updated sample size, all other study parameters, including performance goals, statistical power, and significance level, remain identical to the original approved study
Nominated Raymond Cohen, Chief Executive Officer and board member of Axonics, Inc. and Virginia Kirby, Executive-in-Residence at the Discovery Launchpad at the University of Minnesota’s Office of Technology Commercialization, for appointment to the Board of Directors, pending approval by the Annual Shareholders’ Meeting on June 8, 2022; Don Deyo and Jan Janssen are stepping down, keeping the total number of board members at eight

“I am extremely pleased with our first quarter results and strong execution that resulted in an acceleration in sales and DREAM implants as we progress towards achieving all of our strategic priorities for 2022 and beyond,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer. “On the commercial side, the €660,000 of revenue we booked in the first quarter was roughly equal to the revenue performance from the previous three quarters combined. We now have 15 active implant sites in Germany, and we will continue to add 10 more sites by the end of the third quarter. This growth validates our patient-centric, ‘Going Deep’ strategy of developing Centers of Excellence as we increase therapy penetration at each of these sites. We were also thrilled to implant our first commercial CCC patients in Germany, and we expect continued acceleration in CCC implants following the positive response to our BETTER SLEEP data presentation at the World Sleep Congress in Rome, where we hosted 55 key opinion leaders during the pre-Congress symposium.”

Mr. Taelman continued, “We are also happy with the acceleration in the pace of implants in our DREAM U.S. pivotal study, given recent weekly implant rates, which have increased meaningfully over the last month. We believe we have enough patients enrolled to complete the study by the end of the second quarter of 2022, particularly in light of the FDA’s approval to reduce the sample size to 115 patients. We also continue our dialogue with FDA regarding our IDE submission for our ACCCESS trial for CCC patients in the U.S., and we expect to implant our first patient before the end of this year.”

“Finally, I am thrilled to announce the nominations of Ray Cohen and Ginny Kirby for appointment to the Board of Directors. They will bring a wealth of knowledge that will benefit Nyxoah as we complete DREAM, prepare for our U.S. launch, and advance our pipeline. I look forward to working closely with both of them,” concluded Mr. Taelman.

First Quarter 2022 Results

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS AT AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 – INTERIM CONSOLIDATED STATEMENTS OF LOSS AND OTHER COMPREHENSIVE LOSS

(unaudited) (in thousands)

		For the three months ended March 31
	Notes	2022	2021

Revenue		€ 660	€ 185
Cost of goods sold		( 289)	( 52)
Gross profit		€ 371	€ 133
Research and Development Expense		(3 595)	(3 094)
Selling, General and Administrative Expense		(4 193)	(2 366)
Other income/(expense)		136	4
Operating loss for the period		€ (7 281)	€ (5 323)
Financial income		1 576	4
Financial expense		( 788)	( 325)
Loss for the period before taxes		€ (6 493)	€ (5 644)
Income taxes		( 208)	( 25)
Loss for the period		€ (6 701)	€ (5 669)

Loss attributable to equity holders		€ (6 701)	€ (5 669)
Other comprehensive loss
Items that may be subsequently reclassified to profit or loss (net of tax)
Currency translation differences		( 102)	( 70)
Total comprehensive loss for the year, net of tax		€ (6 803)	€ (5 739)
Loss attributable to equity holders		€ (6 803)	€ (5 739)

Basic Loss Per Share (in EUR)		€ (0.260)	€ (0.256)
Diluted Loss Per Share (in EUR)		€ (0.260)	€ (0.256)

The accompanying notes are an integral part of these condensed consolidated interim financial statements

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS AT AND FOR THE THREE MONTHS ENDED MARCH 31, 2022 – INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited) (in thousands)

	For the three months ended March 31
	2022	2021
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before tax for the year	€ (6 493)	€ (5 644)
Adjustments for
Finance income	(1 576)	( 4)
Finance expenses	788	325
Depreciation and impairment of property, plant and equipment and right-of-use assets	255	164
Amortization of intangible assets	208	211
Share-based payment transaction expense	665	−
Increase/(decrease) in provisions	10	−
Other non-cash items	180	3
Cash generated before changes in working capital	€ (5 963)	€ (4 945)
Changes in working capital
Decrease/(Increase) in inventory	45	( 51)
(Increase)/decrease in trade and other receivables	884	(1 195)
Increase/(Decrease) in trade and other payables	( 392)	2 170
Cash generated from changes in operations	€ (5 426)	€ (4 021)
Interests received	−	1
Income tax paid	(65)	(34)
Net cash used in operating activities	€ (5 491)	€ (4 054)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property, plant and equipment	( 128)	( 169)
Capitalization of intangible assets	(3 412)	(1 606)
(Increase)/decrease in financial assets – current	(44 032)	−
Net cash used in investing activities	€ (47 572)	€ (1 775)
CASH FLOWS FROM FINANCING ACTIVITIES
Payment of principal portion of lease liabilities	( 146)	( 135)
Repayment of other loan	( 21)	( 21)
Interests paid	( 109)	( 105)
Proceeds from issuance of shares, net of transaction costs	130	52
Other financial costs	(2)	−
Net cash generated from financing activities	€ ( 148)	€ ( 209)
Movement in cash and cash equivalents	€ (53 211)	€ (6 038)
Effect of exchange rates on cash and cash equivalents	489	( 55)
Cash and cash equivalents at January 1	€ 135 509	€ 92 300
Cash and cash equivalents at March 31	€ 82 787	€ 86 207

Revenue

Revenue was €660,000 for the first quarter ending March 31, 2022, compared to €185,000 for the first quarter ending March 31, 2021. The increase in revenue was attributable to the Company’s commercialization of the Genio® system, primarily in Germany.

Cost of Goods Sold

Cost of goods sold was €289,000 for the three months ending March 31, 2022, representing a gross profit of €371,000, or gross margin of 56.2%.

Research and Development Expenses

Research and Development expenses were €3.6 million for the three months ending March 31, 2022, versus €3.1 million for the prior year period, reflecting the Company’s investments in the development of next generation versions of the Genio® system as well as ongoing clinical studies, most notably DREAM in the U.S.

Selling, General and Administrative Expenses

General and administrative expenses rose to €4.2 million for the first quarter of 2022, up from €2.4 million in the first quarter of 2021. This was due primarily to increased commercial efforts in Germany and other European markets, as well as investments in Nyxoah’s corporate infrastructure. The Company expects to continue adding headcount across the organization ahead of U.S. commercial launch.

Operating Loss

Total operating loss for the first quarter of 2022 was €7.3 million versus €5.3 million in the first quarter of 2021, driven by the acceleration in our R&D spending, as well as ongoing commercial and clinical activities. Nyxoah realized a net loss of €6.7 million for the quarter ended March 31, 2022, compared to a net loss of €5.7 million for the quarter ended March 31, 2021.

Cash Position
As of March 31, 2022, cash and financial assets totaled €127.8 million on March 31, 2022, compared to €135.5 million on December 31, 2021. Total cash burn was approximately €2.6 million per month during the first quarter of 2022. Nyxoah expects monthly cash burn to increase slightly as the year progresses to account for the commencement of the ACCCESS IDE trial in the U.S., and current cash position provides ample liquidity to get to U.S. commercialization in 2024.

First Quarter 2022 Report
Nyxoah’s financial report for the first quarter of 2022, including details of the consolidated results, are available on the investor page of Nyxoah’s website (https://investors.nyxoah.com/financials).

Conference call and webcast presentation
Nyxoah will conduct a conference call open to the public tomorrow, May 10, 2022, at 2:00 p.m. CET / 8:00 a.m. ET, which will also be webcasted. To participate in the conference call, please dial one of the following numbers:

Conference ID: 8444917

USA:                             (844) 260-3718
Belgium:                       0800 73264
International:                (929) 517-0938

A question-and-answer session will follow the presentation of the results. To access the live webcast, go to https://investors.nyxoah.com/events. The archived webcast will be available for replay shortly after the close of the call.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company’s or, as appropriate, the Company directors’ or managements’ current expectations regarding the Genio® system; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company’s results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, to be filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
Nyxoah
Loic Moreau, Chief Financial Officer
corporate@nyxoah.com
+32 473 33 19 80

Jeremy Feffer, VP IR and Corporate Communications
jeremy.feffer@nyxoah.com

+1 917 749 1494

Attachment

ENGLISH_Q1 2022 Earnings PR – FINAL

May 10, 2022

Synchronoss to Provide Wholesale Process Automation and Management to Brightspeed

Relationship to Support Brightspeed’s Planned Fiber Deployments Across 20-State Footprint

Multi-Year Agreement Features interconnectNOW and Financial Analytics
to Help Orchestrate Service Requests and Manage Trading Partner Expense

BRIDGEWATER, N.J., May 09, 2022 (GLOBE NEWSWIRE) — Synchronoss Technologies Inc. (“Synchronoss” or the “Company”) (Nasdaq: SNCR), a global leader and innovator in cloud, messaging and digital products and platforms, today announced that it has signed a multi-year agreement with Brightspeed, a provider of broadband and telecommunications services expected to have operations in 20 States. Brightspeed will initially be comprised of the incumbent local exchange carrier (ILEC) assets and associated operations of Lumen Technologies (NYSE: LUMN), which are the subject of a pending acquisition by Apollo-managed funds (NYSE: APO).

Brightspeed will utilize two key modules from the Synchronoss networkX Platform – interconnectNOW (iNOW) and Financial Analytics (FA) – for its planned fiber deployments throughout its multi-state territory across rural and suburban regions of the United States.

Brightspeed previously announced plans to invest more than $2 billion to build a network that will bring faster, more reliable Internet and Wi-Fi to communities throughout the Midwest, Southeast, and certain parts of Pennsylvania and New Jersey. The company’s planned fiber optics transformation is expected to reach up to three million homes and businesses over the next five years, including in many places where fiber and advanced technology have not historically been deployed.

“As Brightspeed continues to build out its fiber optics network, iNOW and Financial Analytics will be integral in managing the company’s wholesale carrier operations,” said Chris Hill, Chief Commercial Officer at Synchronoss. “Automating and orchestrating orders throughout the lifecycle will enable Brightspeed to keep pace with customer requests and realize revenue faster.”

“Our partnership with Synchronoss will provide us access to their state-of-the-art platforms to achieve exceptional efficiencies in managing our wholesale carrier orders and trading partner transactions,” said Chris Creager, Chief Administration Officer of Brightspeed. “From end-to-end, iNOW will enable us to track orders and help us deliver world-class connectivity products and services to the communities we look forward to serving.”

The iNOW platform eliminates manual handling of service orders and manages the full lifecycle between customer and supplier via automation and rules-based validation. It provides a single interface and database for all buyer and supplier orders, making it easy to track orders from receipt to fulfillment, reconciles billing, and provides real-time reporting – shortening time to revenue.

The Financial Analytics platform streamlines the management of complex carrier invoicing via automated workflow and intuitive rules engines for auditing, accounting, validation, and payment of invoices. FA empowers service providers such as Brightspeed with the necessary tools and processes to ensure intercarrier expenses are thoroughly analyzed and confirmed prior to payment.

Leading service providers from around the world utilize Synchronoss and the iNOW platform to manage 39 million orders and transactions annually from 5,000 integrated operators.

About Synchronoss

Synchronoss Technologies (Nasdaq: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company’s collection of products helps streamline networks, simplify onboarding, and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market. Hundreds of millions of subscribers trust Synchronoss products to stay in sync with the people, services, and content they love. That’s why more than 1,500 talented Synchronoss employees worldwide strive each day to reimagine a world in sync. Learn more at www.synchronoss.com.

About Brightspeed

Headquartered in Charlotte, N.C. and expected to have assets and associated operations in 20 states, Brightspeed will provide broadband and telecommunications services through a network platform capable of serving more than six million homes and businesses. The company aims to bridge the digital divide by deploying a state-of-the-art fiber network and a customer experience that makes staying connected simple and seamless. Learn more at www.brightspeed.com.

Synchronoss

Media Relations Contact:
Domenick Cilea
Springboard
dcilea@springboardpr.com

Investor Relations Contact:
Matt Glover / Tom Colton
Gateway Group, Inc.
SNCR@gatewayir.com

Brightspeed

Media Relations Contact:
Erik Carlson
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449
pr@brightspeed.com

May 10, 2022

Huawei SD-WAN Recognized as a Gartner® Peer™ Customers’ Choice for Third Year in a Row

SHENZHEN, China, May 10, 2022 /PRNewswire/ — Recently, Huawei announced that it has been named a 2022 Gartner Peer Insights Customers’ Choice for WAN Edge Infrastructure, receiving this distinction for a third straight year. According to the Voice of the Customer report, Huawei SD-WAN received a total of 102 reviews and an overall rating of 4.9/5 stars from customers across industries around the globe as of December 2021. Huawei SD-WAN is also named the “Customers’ Choice” in three categories: Midsize Enterprise, Asia/Pacific, and Europe, the Middle East and Africa (EMEA) in the same report. We think, such distinctions are a testament to the widespread endorsement of Huawei’s SD-WAN solution from customers worldwide.

Huawei SD-WAN recognized as a 2022 Gartner Peer Insights Customers' Choice

As of December 31, 2021, customers across a wide variety of industries, such as finance, manufacturing, and services, had comprehensively reviewed WAN edge infrastructure products and solutions from multiple vendors in terms of product functionality, deployment, O&M, and service support.

For the first time, Gartner has categorized WAN edge infrastructure vendors into four quadrants based on User Interest and Adoption (X-axis) and Overall Rating (Y-axis). Huawei received 100% score in Willingness to Recommend, and scored highest overall rating of 4.9/5 stars. In our opinion, these impressive results fully demonstrate global customers’ recognition of Huawei SD-WAN in terms of industry position, deployment scale, and commercial maturity.

The overall messages from customers who chose Huawei’s SD-WAN solution are extremely positive. Below are some excerpts:

“We are very glad that we choose Huawei SD-WAN finally. According to the deployment result, Huawei SD-WAN can provide very secure, safe and intelligent network connection solution. Their LAN-WAN convergence management helps us reduce a lot of OPEX.” — A customer in the transportation industry^[1]
“Huawei SD-WAN team is very professional and quick response. Huawei SD-WAN team always can provide very quick response and good solution to me. The solution itself is very useful to view the quality of the network.” — A customer in the finance industry^[2]

Huawei is an established player in the SD-WAN market, having served over thousands of customers around the world, including in Italy, Spain, Japan, Thailand, Mexico, and China. As of March 2022, Huawei had been named a Challenger in the Gartner Magic Quadrant™ for WAN Edge Infrastructure for four consecutive years.

^[1] https://www.gartner.com/reviews/market/wan-edge-infrastructure/vendor/huawei/product/cloudwan/review/view/3921638

^[2] https://www.gartner.com/reviews/market/wan-edge-infrastructure/vendor/huawei/product/cloudwan/review/view/3894676

“We’re thrilled to be named a Gartner Peer Insights Customers’ Choice for WAN Edge Infrastructure once again in 2022. This is a testament to Huawei’s longstanding dedication and outstanding market performance in the SD-WAN field. We deeply appreciate the trust of all enterprise customers of our SD-WAN solution,” said Tongqiang Cao, director of Huawei’s SD-WAN solution. “Looking ahead, we will make continued innovation, provide faster, more stable, and smarter network connectivity, and help enterprises to accelerate digital transformation with our SD-WAN solution featuring better user experience.”

For more information about Huawei’s NetEngine AR routers and SD-WAN solution, visit Huawei SD-WAN website: https://e.huawei.com/en/solutions/business-needs/enterprise-network/sd-wan

Source:

1. Gartner Peer Insights ‘Voice of the Customer’: WAN Edge Infrastructure, 24 March 2022

2. Gartner, Magic Quadrant for WAN Edge Infrastructure, 2021

Disclaimer:

1. Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.

2. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

Photo – https://mma.prnewswire.com/media/1814260/image_1.jpg

May 10, 2022

CGTN: China stresses the need to bring more stability to an age of instability

BEIJING, May 10, 2022 /PRNewswire/ — China on Monday highlighted the pressing need to bring more stability and certainty to an age of instability and transformation, given the ongoing complex changes in the international landscape and a marked rise in difficulties and challenges for global security and development.

During a virtual meeting with German Chancellor Olaf Scholz, Chinese President Xi Jinping called on the two countries to work together to maintain a sound and steady relationship to contribute significantly to world peace and tranquility.

Xi’s latest call came after he urged the EU to work with China to add stabilizing factors to a turbulent world during a virtual meeting with the EU chiefs on April 1.

During Monday’s talks, Xi said it is particularly important for China and Germany, both major countries of substantial influence, to maintain sound and steady growth of bilateral ties and better harness the stabilizing, constructive and steering role of this relationship.

Both countries should stick to the keynote of dialogue and cooperation in their relations, and make good use of bilateral dialogue and cooperation mechanisms, said Xi.

He continued that the two sides can conduct dialogue in such areas as climate change, macroeconomic policy, financial stability, energy security, food security and the stability of industrial and supply chains.

China and Germany should also tap the potential for cooperation, such as on new technologies, including environmental protection, trade in services, artificial intelligence and digitalization, said the Chinese president.

The two sides should stand for true multilateralism, uphold international fairness and justice, promote an open world economy, and make global development more balanced, coordinated and inclusive, Xi said.

Scholz noted the very good development of Germany-China relations in recent years and called on the two sides to carry forward the good tradition and keep up the sound momentum of bilateral relations.

The two countries will have a dialogue on maintaining stable global supply chains, macroeconomic policy coordination and others, and step up cooperation in a wide range of areas, including trade and investment, climate change and COVID-19 response, said the German leader.

He added that Germany welcomes China’s commitment to expanding high-standard opening-up, which will bring more opportunities to the country.

China and Germany, now all-round strategic partners, will celebrate the 50th anniversary of the establishment of diplomatic ties in October.

‘China-Europe relationship not controlled by any third party’

Xi underscored that China and the EU are comprehensive strategic partners and each other’s opportunity, and that the two sides have far more common interests than differences.

China supports the strategic autonomy of the EU, he reiterated.

“The China-Europe relationship is not targeted at, subjugated to, or controlled by any third party,” said Xi, noting that is a strategic consensus that both sides must follow in the long run.

In the face of geopolitical crises, China and the EU need to advocate dialogue and cooperation and offset complex changes in the international landscape with the stability of China-EU relations.

Xi expressed his hope for Germany to play a positive role in the steady and sound development of China-EU relations.

Scholz, for his part, said Germany is prepared to enhance communication and coordination with China on the multilateral front and promote the sound development of Europe-China relations.

‘Ukraine crisis bringing European security at a crossroads’

On the situation in Ukraine, Xi said China has been working in its own way to promote peace and defuse tensions.

The Ukraine crisis has once again brought European security to a crossroads, he said, adding that it is important to make every effort to prevent the conflict from intensifying or magnifying to a point of no return.

The Chinese president called on the European side to show historical responsibility and political wisdom, bear in mind the long-term stability of Europe and promote a solution in a responsible manner.

“The security of Europe should be kept in the hands of Europeans themselves,” he said.

China has reiterated on many occasions that it supports Europe in playing a positive role in promoting peace talks and in the eventual establishment of a balanced, effective and sustainable European security architecture.

https://news.cgtn.com/news/2022-05-09/President-Xi-holds-talks-with-German-Chancellor-Scholz-via-video-link-19TFo9OduuI/index.html

Video – https://www.youtube.com/watch?v=mbP-p9ivMEE

May 10, 2022

‫تصنيف تشارلي ميتشل، الأسترالي البالغ من العمر 16 سنة، الذي يقوم نارادا مايكل والدن بإنتاج أعماله وهو المعروف بإنتاج أعمال ويتني هيوستن، لأول مرة في المرتبة الأولى على الرسم البياني المعاصر للبالغين، متفوقا على ميك جاغر وبيلي جويل.

لوس أنجلوس، 10 ماي/أيار 2022 / PRNewswire / — شهد تشارلي ميتشل، المغني البالغ من العمر 16 عاما من غولد كوست، تصنيف أغنيته سكاي روكيت skyrocket في المرتبة الأولى على الرسم البياني المعاصر للبالغين. يمكن لإدارة ESW أن تؤكد رسميا أن إنتاج Narada Michael Walden لأغنية ” إيفن أفتر Even After ” لبريان إيفانز، وهي أغنية كتبها إيفانز عن والدته، تصدر الرسم البياني المعاصر للبالغين. دهش كل من جيسي ستينجر وإيفانز، اللذان أنتجا الأغنية مع تأليف تشارلي ميتشل للحن، بالأخبار.

Charlie Mitchell, produced at Narada Michael Walden, debuts at #1 on the Adult Contemporary charts, surpassing Mick Jagger and Billy Joel. The song, "Even After," was written by Brian Evans, Jesse Stenger, with melody by Charlie Mitchell.

سيظهر تشارلي ميتشل لأول مرة على الصعيد الوطني في أستراليا في العرض الصباحي استوديو 10 يوم الأربعاء ¹¹ ماي/أيار 2022، متجاوزا ميك جاغر وبيلي جويل في مخططات PlayMPE ، الرائدان في توزيع الموسيقى مباشرة لبرامج الراديو.

قال ستينجر: “إن الطلبات تتكدس علينا في هذه المرحلة. استيقظنا هذا الصباح على صندوق بريد إلكتروني ممتلئ جدا لدرجة أن الناس كانوا يتصلون بنا ليخبرونا أن رسائل البريد الإلكتروني التي أرسلوها تعود إليهم”.

أضاف إيفانز: “إنها ليست بمفاجأة بالنسبة لي”. “عرفت اللحظة التي رأيته فيها”.

كتب إيفانز أغنية “إيفن أفتر Even After ” بطريقة فريدة. ينقل المقطع الأولى كلمات شخص محب فقد شخصا بطريقة ما، في حين أن المقطع الثانية والجسر هو الذي فقدته في التحدث إليك.

“عندما كنت أكتبها، واستغرق الأمر سنوات لأكون قادرا على تجاوز وفات والدتي المأساوي والمفاجئ، كنت أعرف أنه حتى كمغني، لا يمكنني أن أحمل نفسي على غنائها. لقد كنت مرتبطا جدا بها. عندما اكتشفت تشارلي على وسائل التواصل الاجتماعي، علمت أنه يعاني من الضعف الذي من شأنه أن يمنح الطفل فرصة. سيفسرها الناس بطريقتهم الخاصة. يعتقد البعض أن الأمر يتعلق بالانفصال، والبعض يعتقد أن الأمر يتعلق بوفات شخص ما “. “ما لم أتوقعه هو مدى موهبة تشارلي، وقدرته الفريدة على” روحه القديمة ” في تفسير أغنية رغم صغر سنه. إنه أمر رائع حقا”.

كانت كلمات نارادا مايكل والدن أبسط بكثير: “تشارلي هو نجم في طور التكوين”. أنا سعيد لأن برايان أحضره إلي ولدينا الكثير من العمل لنقوم به معا “.

يمكن تنزيل أغنية “إيفن أفتر Even After ” على Apple iTunes و Spotify وعلى أي تطبيق آخر لتنزيل الموسيقى. موقعه الرسمي على الإنترنت هو charliemitchellmusic.com ، وحسابه على الفيسبوك هو Facebook.com/CharlieMitchellMusic حيث كان له أكثر من 35000 متابع قبل أن يقوم والدن بإنتاج أعماله.

يمكن تصفح الرسم البياني على موقع: https://daily.plaympe.com/adult-contemporary-weekly-top-20-downloads/

مصدر الصورة – https://mma.prnewswire.com/media/1813055/Charlie_Mitchell_Even_After_2.jpg

May 10, 2022

‫ شبكة تلفزيون الصين الدولية (CGTN): عيد الأم: قصص شي جين بينغ ووالدته

بكين، 10 ماي/أيار 2022 / PRNewswire / — يشارك الناس في عيد الأم، الذي يصادف يوم الأحد الثاني من شهر ماي/أيار من كل عام، في جميع أنحاء العالم قصصا عن أمهاتهم ويعبرون عن حبهم وامتنانهم للمرأة التي أحضرتهم إلى هذا العالم.

يعتبر الآباء والأمهات قدوة للأطفال، ولا يستثنى من ذلك الرئيس الصيني شي جين بينغ.

ذكر قصصا عن كيفية تأثير والدته تشي شين عليه طوال حياته.

انضمت تشي، المولودة سنة 1926، إلى الحزب الشيوعي الصيني سنة 1943 حين كانت في الخامسة عشرة من عمرها، وأصبحت من أشد المؤيدين لقيم الحزب ومعتقداته.

قالت تشي ذات مرة: “يجب على الآباء والأمهات وكبار السن نقل الأخلاق الحميدة لأبنائهم في صغرهم، ومساعدتهم على تبني النزاهة الأخلاقية والنية الحسنة، حتى يتمكنوا من النمو ليصبحوا أشخاصا يساهمون في تنمية البلاد والمصلحة العامة”.

“خدمة الوطن والولاء له”

عندما كان شي يبلغ من العمر خمس أو ست سنوات، اشترت له لأمه كتبا مصورة وأخبرته قصة يو في، الجنرال الأسطوري الذي خاض معارك للدفاع عن أمته بولاء خلال عهد سلالة سونغ الحاكمة (1127-1279).

أخبرت الأم الصبي كيف قامت والدة يو فاي بوشم أربعة أحرف صينية، والتي تُترجم حرفيا بِـ “اخدم البلاد بولاء” على ظهر ابنها.

يتذكر شي قائلا: “قلت لا بد أنه كان من المؤلم وشم هذه الكلمات على الظهر”. “لكن أمي قالت إنه على الرغم من الألم، إلا أنه حفظها عن ظهر قلب.”

جعل شي تلك الكلمات منذ ذلك الحين هدف يسعى وراءه في الحياة.

طاعة الوالدين

بصفته ابنا يطيع وبارا بوالديه، يتحدث شي مع والدته ويتمشى معها كلما كان لديه وقت. وُضعت صورة له وهو يمشي جنبا إلى جنب مع والدته على رفوف كتبه.

خلال عيد الربيع لعام 2001، لم يتمكن شي، الذي كان آنذاك حاكم مقاطعة فوجيان جنوب شرق الصين، من الاجتماع مع والديه بسبب العمل.

اتصلت تشي بابنها، قائلة طالما أنه يبذل قصارى جهده في عمله، فإنه يظهر لها ولأبيه طاعته وبره بهم.

لقد ألهمت كلمات الدعم التي قدمتها بشكل كبير شي، لخدمة الجمهور بهدف تحقيق حياة كريمة للعائلات الصينية.

قال شي مرارا وتكرارا إنه “يحب الناس تماما كما يحب والديه”.

نقل تقاليد الأسرة

عاشت تشي حياة بسيطة، والتي أصبحت تقليدا للعائلة. أسلوب حياتها والجو العائلي يوجهان قيم شي اليوم.

“الشخص الذي لا يخفق في منع نفسه من أن يصبح فاسدا وأن يكون منضبطا ذاتيًا سيصبح شخصًا بلا شجاعة. ضع في اعتبارك أن الصدق نعمة والجشع لعنة أثناء تكوين تصور صحيح للسلطة والمكانة والمصالح”، هذا ما كتبته تشي ذات مرة في رسالة لشي، تذكره بالانضباط الذاتي.

وقد أدرج شي هذه المعتقدات في أيديولوجيته وممارساته في الحكم.

أمضت تشي سنة 2000 40 يوما في زيارة منطقة القاعدة الثورية القديمة للحزب الشيوعي الصيني في شنشي وقانسو ونينغشيا. في تشاوجين، وسط المنطقة، شاهدت الفصول الدراسية المتهالكة في مدرسة ابتدائية محلية وعبأت أسرتها للتبرع بمبلغ 150 ألف يوان لإعادة بناء المدرسة.

في ماي/أيار 2018، كتب طلاب المدرسة رسالة إلى شي، أبلغوه فيها عن دراستهم وتطوير المدرسة. بعد أسبوع من ذلك، أجابهم الرئيس، وشجعهم على اكتساب ونقل روح الحزب الشيوعي الصيني بإجراءات ملموسة.

عيد الأم: تعتبر قصص شي جين بينغ ووالدته بمثابة قدوة للأطفال، وذلك ليس استثناء للرئيس الصيني شي جين بينغ.